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Abstract Platelet endothelial cell adhesion molecule-1 (PE-
CAM-1/CD31) is a member of the immunoglobulin (Ig) super-
family that has distinctive features of an immunoreceptor based
upon its genomic structure and the presence of intrinsic immu-
noreceptor tyrosine inhibitory motifs (ITIMs) in its ligand bind-
ing polypeptide. This has lead to its subclassi¢cation into the
Ig-ITIM superfamily. Its amino-terminal Ig-like domain of PE-
CAM-1 is necessary for its homophilic binding, which plays
an important role in cell^cell interactions. Its intracellular
ITIMs serve as sca¡olds for recruitment of signalling molecules
including protein-tyrosine phosphatases to mediate its inhibitory
co-receptor activity. Increasing evidence has implicated PE-
CAM-1 in a plethora of biological phenomena, including mod-
ulation of integrin-mediated cell adhesion, transendothelial
migration, angiogenesis, apoptosis, cell migration, negative
regulation of immune cell signalling, autoimmunity, macrophage
phagocytosis, IgE-mediated anaphylaxis and thrombosis. In this
review, we discuss some of the new developments attributed to
this molecule and its unique roles in biology.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Platelet endothelial cell adhesion molecule-1 (PECAM-1/
CD31) is an immunoglobulin (Ig) superfamily member ex-
pressed on the surface of platelets and leukocytes, and is
also concentrated at the lateral junctions of endothelial cells.
PECAM-1 is composed of six extracellular Ig-domains, a
transmembrane domain and a cytoplasmic domain. Its ligands
include itself (homophilic interaction involving Ig-domain 1),
KvL3 and CD38 (heterophilic interaction involving Ig-domains
1^3) [1]. Since its original cloning, much has been learned
about the role of PECAM-1 in mediating various cellular
interactions. PECAM-1 has been implicated in various biolog-
ical functions such as leukocyte transmigration, cell migra-
tion, angiogenesis, cell signalling and cell adhesion. Biochem-
ical and functional studies have shown that PECAM-1
contains intracytoplasmic immunoreceptor tyrosine inhibitory
motifs (ITIMs), that upon phosphorylation can mediate an
inhibitory function through recruitment and activation of pro-
tein-tyrosine phosphatases (PTPs), predominantly SHP-2 and
to a lesser extent, SHP-1 [2^5]. Therefore, PECAM-1 is now
considered a member of the Ig-ITIM superfamily, a subset of
the conventional Ig-superfamily [3,4,6] (Fig. 1).
2. Expression and structure of PECAM-1
PECAM-1 has a relative molecular weight of 130-kDa and
is di¡erentially glycosylated involving N-linked and O-linked
glycosylation sites. The open reading frame of PECAM-1 is
composed of 16 exons, corresponding to a signal peptide, six
C2-type Ig-domains, a transmembrane region and a cytoplas-
mic domain [7]. The localization of the PECAM-1 gene is
found on the human chromosome 17q23 and the mouse chro-
mosome 6 [8]. There are several alternatively spliced variants
of PECAM-1 that are expressed in a cell-type and species-
speci¢c pattern in human, rat and mouse that arise as a result
of alternative splicing of either the transmembrane or cyto-
plasmic domain exons. Examples include the delta-exon 14
form and the delta-13 form found in endothelial cells [9,10],
a soluble form of PECAM-1 that is generated by splicing out
of exon 9, which encodes the transmembrane domain [11],
murine PECAM-1 delta-12,15, and delta-14,15 from develop-
ing cardiac endothelium [12] and murine PECAM-1 delta-
12,14 from brain [13]. The PECAM-1 mRNA is highly ex-
pressed in lung, heart and kidney and to a lesser extent brain
and liver [13]. PECAM-1 is broadly expressed in blood, im-
mune and vascular cells. It is expressed at high density at the
lateral borders of endothelial cells and at a lower density on
the surface of hematopoietic and immune cells (macrophages,
neutrophils, monocytes, mast cells, natural killer cells, naive
T cells, naive B cells and platelets) [1]. It is not expressed on
¢broblasts, epithelial cells or red blood cells.
3. Ligand interactions of PECAM-1
There is now considerable evidence that PECAM-1 medi-
ates cellular adhesive interactions by homophilic binding of
PECAM-1 on adjacent cells involving the distal N-terminal
Ig-domain 1 and amino acid contact sites, D11, D33, K50,
D51 and K89 on PECAM-1 [14^16]. Human^mouse chimeric
studies have demonstrated species speci¢city for PECAM-1
homophilic interactions [14]. Apart from homophilic binding,
heterophilic adhesive interactions of PECAM-1 with several
ligands including integrin KvL3, CD38, 120-kDa ligand on
T cells and heparin-dependent proteoglycans have been pro-
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posed to interact in regions encompassing Ig-domains 1^3 of
PECAM-1 [17^20]. Subsequent studies have shown that cell
surface glycosaminoglycans do not serve as a ligand for PE-
CAM-1 [21]. Ligand binding speci¢city of PECAM-1 can be
regulated by loss of tyrosine residue ITIM, Y686F from exon
14 of the cytoplasmic domain or its phosphorylation resulting
in a change in ligand speci¢city from heterophilic to homo-
philic binding [22].
Recent studies have suggested that cell surface expression of
PECAM-1 is further regulated by receptor shedding involving
a matrix metalloproteinase-dependent mechanism and by re-
ceptor cleavage involving caspase activity [23]. PECAM-1
shedding involves the generation of a soluble 100-kDa extra-
cellular domain form and a truncated 28-kDa fragment con-
taining the transmembrane and cytoplasmic domain of PE-
CAM-1 [23]. This truncated 28-kDa fragment appears to
have preferential recruitment of Q-catenin and SHP-2 but
not L-catenin that may enhance signalling capabilities.
4. Association of signalling molecules with PECAM-1/CD31
The human PECAM-1 cytoplasmic domain contains 12 ser-
ine, ¢ve tyrosine and ¢ve threonine residues, which could
serve as docking sites for recruitment of cytosolic signalling
molecules. Examination of the phosphorylation status of PE-
CAM-1 in platelets under di¡erent conditions of stimulation
has revealed that induction of serine phosphorylation of PE-
CAM-1 is an early event in platelet activation and coincides
with cytoskeletal association [2,24]. This is in contrast to the
induction of tyrosine phosphorylation of PECAM-1, which is
generally a later event requiring predominantly integrin KIIbL3
aggregation-dependent and to a lesser extent integrin KIIbL3
aggregation-independent mechanisms [2,16,25]. Platelet ago-
nists, collagen, GPVI-selective convulxin or collagen-related
peptide (CRP) and thrombin have been shown to induce ty-
rosine phosphorylation of PECAM-1 under conditions of
platelet activation [25,26]. These studies suggested that pro-
tein-tyrosine kinase (PTK)-dependent signalling cascades such
as collagen GPVI/FcR-Q chain may be functionally linked to
PECAM-1-dependent signalling pathways, as tyrosine resi-
dues in ITIMs need to be phosphorylated by Src family kinase
members to create docking sites for cytoplasmic Src homol-
ogy 2 (SH2) domain-containing PTPs. Interestingly, mutagen-
esis studies of putative tyrosine residues converted to phenyl-
alanine residues in the PECAM-1 ITIMs revealed that
tyrosine residues, 663 and 686 account for the entire tyrosine
phosphorylation of PECAM-1 and are required for PTP re-
cruitment under conditions of pervanadate stimulation [27].
No evidence of threonine phosphorylation of PECAM-1 in
platelets has been detected to date.
Several mechanisms of induction of tyrosine phosphoryla-
tion of PECAM-1 have been described. These include integrin
KIIbL3-mediated platelet aggregation, mechanical shear stress
on endothelial cells, co-aggregation of FcORI receptor on ba-
sophils, engagement of the T-cell receptor antigen complex
(TCR) on T cells, engagement of the B-cell receptor antigen
complex (BCR) on B cells, integrin engagement on extracel-
lular matrix, cross-linking with anti-PECAM-1 antibodies,
growth factor stimulation including vascular endothelial
growth factor, GPVI-mediated platelet activation (via colla-
gen or convulxin) and treatment with PTP inhibitors (vana-
date and pervanadate) [2,4,25,28^32].
5. Src family kinase members
Several investigations have been undertaken to de¢ne the
PTKs responsible for inducing tyrosine phosphorylation of
PECAM-1. Overexpression of p60cSrc in endothelial cells re-
vealed that p60cSrc could induce the tyrosine phosphorylation
of human PECAM-1 [33]. In vitro p60cSrc was shown to
phosphorylate a GST fusion protein containing the PE-
CAM-1 cytoplasmic domain [14,22]. Transient overexpression
of Src and Csk family members with mouse PECAM-1 in a
COS cell system revealed that p56lck, p56lyn, p53lyn, p60cSrc
and p50csk but not Syk, Itk or Pyk2 were capable of inducing
tyrosine phosphorylation of the PECAM-1 cytoplasmic do-
main [34]. In the context of platelets, Fyn, Lyn, Src, Yes
and Hck PTKs were shown to co-immunoprecipitate with
Fig. 1. Schematic representation of several ITIM-bearing receptors. Members of the Ig-ITIM superfamily include protein zero related, PZR, the
low-a⁄nity IgG receptor, FcQRIIB1, killer inhibitory receptor, KIR, the signal regulatory proteins, SIRPs, the Ig-like transcripts, ILT-2,3,
paired Ig-like receptors, PIR-B, PECAM-1 and C-type lectin members, Ly49 and NKG2A/B.
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PECAM-1 [25]. The importance of Fyn tyrosine kinase was
further substantiated by showing that PECAM-1 tyrosine
phosphorylation was reduced in Fyn-de¢cient mouse platelets
[25]. In the context of p56lck-de¢cient Jurkat T cells, the ab-
sence of p56lck resulted in loss of PECAM-1 tyrosine phos-
phorylation upon cross-linking the TCR complex and this
could be reversed upon reconstitution of p56lck in these cells
[5].
6. PTPs, SHP-1 and SHP-2
The ¢rst identi¢cation of PECAM-1 ITIM consensus se-
quences was reported by Jackson et al. [2]. Upon induction
of phosphorylation of putative tyrosine residues in the ITIMs
of PECAM-1, SHP-1 and SHP-2 PTPs were found to
be recruited and activated. This interaction is direct and re-
quired the interaction of the SH2 domains of the PTPs with
phosphorylated ITIM sequences found in exons 13 and
14 of PECAM-1 cytoplasmic domain (VQpY663TEV and
TVpY686SEV). Importantly, these ITIM sequences classically
conform to the expected consensus sequences required for
PTP binding (I/VxxYxxL/V/Ixs 20a.a.I/VxYxxL/V/I). Muta-
genesis studies revealed that Y663F and Y686F mutations in
the PECAM-1 cytoplasmic domain led to loss of PECAM-1
tyrosine phosphorylation and recruitment of PTPs such as
SHP-2 [27]. Surface plasmon resonance studies revealed that
the ITIM consensus sequences bind SHP-2 at a ¢ve-fold high-
er a⁄nity than SHP-1, suggesting that SHP-2 may be the
preferred PTP [3]. Importantly, the association of SHP-1
and SHP-2 with tyrosine phosphorylated PECAM-1 was
found to occur under physiologically relevant conditions of
integrin KIIbL3-mediated platelet aggregation and to a lesser
degree upon platelet activation [2,3]. Subsequent studies re-
ported PECAM-1 association with SHP-2 under conditions
of FcORI receptor aggregation in RBL-2H3 cells [29] and
following mechanical stimulation of vascular endothelial
cells [35]. Furthermore, transient overexpression of mouse
PECAM-1 in COS cells revealed that phosphorylation of
PECAM-1 by Src family kinases was su⁄cient to induce bind-
ing of both SHP-2 and SHP-1. This binding was dependent
upon the integrity of the ITIM tyrosine residues, 663 and 686
[34].
7. Inositol polyphosphate 5P-phosphatase, SHIP
Phosphopeptide studies revealed that the inositol polyphos-
phate 5P-phosphatase, SHIP, interacted predominantly with
the pY686 containing PECAM-1 cytoplasmic domain peptide
[36]. Subsequent studies revealed that SHIP was capable of
interacting with sequences surrounding tyrosine 686 in a non-
phosphotyrosine-dependent manner [4]. Importantly, under
conditions of co-aggregation of BCR complex with a chimeric
receptor encompassing FcQRIIB-PECAM-1 cytoplasmic do-
main in DT40 B cells, PECAM-1-mediated inhibitory signal-
ling was not dependent on the presence of SHIP [4].
Recent studies with the prototypic ITIM-bearing receptor,
FcQRIIB have suggested that the consensus sequence IxpYxxL
is required for SHP-1/2 binding, while xxpYxLL is the SHIP1/
2 binding site in the FcQRIIB ITIM [37]. By applying these
consensus sequences to the PECAM-1 ITIMs, it would appear
that Y663 ITIM precisely con¢rms to the SHP-1/2 binding
site, while Y686 ITIM conforms at Y+3 residue, but not
Y32 residue. Based upon the Y686 PECAM-1 ITIM consen-
sus sequence, it is still not clear why SHIP would be prefer-
entially recruited by this sequence in preference to the Y663
ITIM consensus sequence. The Y+3 residue conforms to the
SHIP1/2 binding site, but not Y+2 residue. Further studies
will be required to clarify this issue.
8. Phospholipase C (PLC)-Q1
Phosphopeptide studies revealed that PLC-Q1 interacted
with both pY663 and pY686 containing PECAM-1 cytoplas-
mic domain peptides. The pY663 PECAM-1 peptide interac-
tion appeared to be of higher a⁄nity compared to pY686
PECAM-1 peptide interaction [36]. Examination of the PE-
CAM-1 cytoplasmic ITIM residues demonstrated they loosely
conform to the classical PLC-Q1 consensus sequences (pYLEL
for N-terminal SH2 recognition) [37].
9. L- and Q-catenin
Using co-immunoprecipitation studies, it has been shown
that a proportion of PECAM-1 associates with L-catenin
[38]. PECAM-1 appears to be involved in controlling the lo-
calization and levels of tyrosine phosphorylated L-catenin by
recruiting it to the plasma membrane and cell^cell junctions
[39]. Mutation of tyrosine residues 663, 686 and 701 of
PECAM-1 to phenylalanine residues did not a¡ect L-catenin
binding and co-immunoprecipitation with PECAM-1, indicat-
ing that tyrosine phosphorylation and SHP-2 recruitment
were not required for L-catenin association [39]. Apart from
L-catenin/PECAM-1 association, Q-catenin can also associate
with PECAM-1 which is regulated by PECAM-1 serine/threo-
nine phosphorylation but not tyrosine phosphorylation [40].
Protein kinase C (PKC)-mediated PECAM-1 phosphorylation
was found to play a key role in modulating PECAM-1/Q-cat-
enin association and localization to cell^cell junctions [40].
Whether the PECAM-1 cytoplasmic domain can directly or
indirectly bind L-catenin and the relevant binding sites are
not known. Further studies will be required to resolve this
issue.
10. Phosphoinositide 3-kinase (PI3-kinase)
A functional association of PECAM-1 and PI3-kinase has
been reported in human neutrophils [41]. Following PECAM-
1 cross-linking with speci¢c antibodies and immunoprecipita-
tion of PECAM-1, the p85 subunit of PI3-kinase was detect-
able by immunoblotting in a time-dependent manner [41].
Examination of the PECAM-1 cytoplasmic domain tyrosine
residues does not reveal a classical PI3-kinase consensus se-
quence (pYMxM). Therefore, it is possible that PI3-kinase
does not directly associate with the PECAM-1 cytoplasmic
domain, but is part of a multimeric signalling complex involv-
ing PECAM-1/SHP-2 with Grb2-associated binder 2 and PI3-
kinase.
11. Delivery of inhibitory signalling
Based upon several studies, it would appear that co-engage-
ment of active immunoreceptor tyrosine activation motif
(ITAM)-mediated signalling (BCR, Fc receptor (FcORI), col-
lagen GPVI/FcR-Q chain receptor complex, platelet Fc recep-
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tor (FcQRIIA) with ITIM-mediated signalling (PECAM-1) is
required for delivery of ‘outside-in’ signalling to mediate PTP-
dependent inhibitory signalling. In vitro studies have demon-
strated that in order for PECAM-1 to mediate inhibitory sig-
nalling, its requires its cytoplasmic domain, intact ITIMs and
speci¢c PTPs [4,5]. The extracellular ligation requirements of
PECAM-1 are less well characterized. It would appear that
homophilic ligation of PECAM-1 is an important component
of ‘outside-in’ signalling of PECAM-1 [26,42]. In vitro studies
have suggested that PECAM-1 dimers, but not oligomers are
e⁄cient in supporting trans PECAM-1 homophilic interac-
tions. Modulation of the adhesive function of integrins ap-
pears to require oligomerization of PECAM-1 within the
plane of the membrane [43].
12. Cellular functions of PECAM-1
12.1. Function of PECAM-1 in B and T cells
In humans, expression of PECAM-1 is restricted to naive B
cells and is down-regulated upon di¡erentiation to memory B
cells [44]. PECAM-1 is also preferentially expressed by the
naive (CD45RAþ) CD8þ T-cell subset. PECAM-1 expression
is down-regulated from the majority of CD4þ, and about 50%
of CD8þ T cells as they di¡erentiate from naive to memory T
cells [45,46]. This is in contrast to the murine lymphoid envi-
ronment, where PECAM-1 is expressed on 95% splenic lym-
phocytes and is represented across all B-2, B-1a and T-cell
subsets [47]. In vitro studies using chicken DT40 B-cell lines
stably transfected with FcQRIIB1-PECAM-1 wild-type (WT)
and FcQRIIB1-PECAM-1 Y663,686F fusion proteins has re-
vealed that the PECAM-1 cytoplasmic domain is capable of
delivering a negative inhibitory signal that is dependent on
intact ITIMs and speci¢c PTPs, predominantly involving
SHP-2 and to a lesser extent SHP-1 [4]. Co-ligation of the
BCR complex with FcQRIIB1-PECAM-1 results in recruit-
ment and activation of the PTP, SHP-2 by PECAM-1 ITIMs
to inhibit downstream e¡ector responses including Ca2þ £ux
and nuclear factor activation of transcription (NFAT) tran-
scriptional activation [4]. Upon BCR ligation, PECAM-13=3
B cells exhibit enhanced calcium responses and increased B-
cell proliferation [47]. This hyper-responsiveness was particu-
larly noticeable at subthreshold concentrations of agonist used
in the assay systems. PECAM-13=3 mice show abnormalities
in B-cell development including reduced mature B-2 cells in
the periphery and an overrepresentation of the B-1a pool in
the peritoneal cavity.
In vivo adoptive transfer experiments using CFSE-labelled
PECAM-1þ=þ and PECAM-13=3 lymphocytes were found to
exhibit normal homing to the spleen but showed a 50% re-
duction of PECAM-13=3 B cells by day 30 after transfer
compared to PECAM-1þ=þ B cells [47]. These studies sug-
gested that the de¢ciency of mature recirculating B cells ob-
served in the periphery of PECAM-13=3 mice may be attrib-
uted to hyper-responsive BCR signalling of PECAM-1-
de¢cient B cells that may trigger these cells to undergo spon-
taneous apoptosis.
Functional evaluation of T-cell subpopulations has revealed
that PECAM-1-negative CD4þ T cells can provide more ef-
fective T helper cell function to recall antigens; secrete more
interleukin-4 and provide more co-operation in B-cell Ig syn-
thesis than PECAM-1-positive CD4þ T cells. These di¡eren-
ces in T-cell responsiveness in the absence of PECAM-1 could
be attributed to its inhibitory receptor function. There is
emerging evidence to suggest that PECAM-1 may be an im-
portant regulator of antigen-induced cell activation in the
context of T lymphocytes. Induction of immune stimulation
of the TCR complex on Jurkat T cells leads to tyrosine phos-
phorylation of PECAM-1 and recruitment of PTPs, SHP-2
and possibly SHP-1 [29]. Using p56lck-de¢cient Jurkat T cells,
it was shown that PECAM-1 failed to become tyrosine phos-
phorylated, which was restored upon reconstitution with WT
p56lck PTK [5]. These studies indicated that in T cells, p56lck is
the putative PTK responsible for phosphorylating PECAM-1
ITIMs. In addition, co-ligation of the ITIM-bearing PECAM-
1 with TCR complex on Jurkat T cells led to a transient block
in calcium mobilization [48]. Collectively, these observations
suggest that PECAM-1 serves as a negative regulator of TCR-
mediated signalling events.
12.2. Induction of autoimmune disease and breakdown of
peripheral tolerance in PECAM-1-de¢cient mice
Studies on PECAM-1-de¢cient mice in a C57BL/6 back-
ground have shown that PECAM-1 acts as a negative regu-
lator of immune responses in vivo and serves to prevent emer-
gence of autoimmune disease with age [47]. These mice have
increased levels of serum IgM and elevated IgG2a, IgG2b,
IgG3 and IgA responses to T-cell-independent antigen DNP-
Ficoll, but not T-cell-dependent antigen DNP-KLH. PE-
CAM-1-de¢cient mice develop anti-nuclear antibodies by 9
months of age with titers as high as 3200 and speci¢city for
double stranded DNA. These PECAM-1-de¢cient mice also
develop evidence of proteinuria with age and histological ex-
amination of their kidneys reveals evidence of immune-com-
plex deposition in their glomeruli that was not observed in
age- and sex-matched control mice [47]. These features are
consistent with the development of autoimmune lupus-like
glomerulonephritis with age.
Recognition that PECAM-1 has a functional role in regu-
lating immunomodulation has lead to its inclusion in the list
of known B-cell co-receptors including CD22, PD-1 and
CD72 [47]. Biochemical and functional studies have revealed
that PECAM-1 preferentially utilizes SHP-2 PTP, while
CD22, PD-1 and CD72 preferentially utilize SHP-1 PTP to
modulate BCR-mediated signalling. Therefore, it is likely that
these PTPs may regulate di¡erent signalling pathways and
regulate B-cell responsiveness in di¡erent contexts. Further
studies will be required to examine whether di¡erent B-cell
co-receptors utilize similar or di¡erent pathways to modulate
BCR-mediated signalling.
In an inducible mouse model of autoimmune encephalo-
myelitis (EAE) that resembles the human autoimmune disease
of multiple sclerosis, PECAM-1-de¢cient mice demonstrated
an early onset of clinical symptoms of EAE and increased
immune cell tra⁄cking into the central nervous system during
early stages of the disease [49].
12.3. Function of PECAM-1 in platelets
Even though PECAM-1 was originally identi¢ed to be ex-
pressed in platelets over 10 years ago, its functional impor-
tance has been unclear. As no individuals have been reported
that have qualitative or quantitative defects in PECAM-1, the
availability of PECAM-1-de¢cient mice has provided the op-
portunity to directly test its involvement in hemostasis and
thrombogenesis. Initial assessment of PECAM-1-de¢cient
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mice demonstrated that megakaryocyte and platelet produc-
tion was normal with no abnormality detected in ADP-in-
duced platelet aggregation [50]. PECAM-1-de¢cient mice dis-
play a prolonged bleeding time, which has been attributed to a
vascular defect rather than a platelet defect, as irradiation of
PECAM-1-de¢cient mice and reconstitution of the hemato-
poietic cell compartment containing PECAM-1-positive plate-
lets did not correct the bleeding time [51]. As PECAM-1 is
¢rst Ig-ITIM-bearing receptor to be characterized in platelets,
it is likely that it would negatively modulate ITAM-bearing
cascades including collagen receptor GPVI/FcR-Q chain and
FcQRIIA-mediated signalling. Under conditions of static
platelet adhesion, PECAM-13=3 platelets showed enhanced
platelet adhesion on immobilized collagen but not ¢brinogen
or bovine vWF matrix compared to WT platelets, indicating a
selectivity for collagen. PECAM-1-de¢cient platelets displayed
enhanced platelet aggregation and secretion responses on
stimulation with varying doses of collagen and CRP, although
the responses to ADP and thrombin over a wide dose range
were una¡ected [26,52]. Using both human and mouse mod-
els, PECAM-1 was demonstrated to act as a physiological
negative regulator of platelet^collagen interactions that may
function to negatively limit growth of platelet thrombi on
collagen surfaces [26]. Speci¢cally, under conditions of £ow,
human thrombus formation on immobilized collagen was re-
duced in a dose-dependent manner by human PECAM-1-Ig
chimera but not control IgG. Platelets derived from PECAM-
1-de¢cient mice formed larger thrombi when perfused over a
collagen matrix under £ow at a shear rate of 1800 s31 com-
pared to WT mice [26]. These studies demonstrate that PE-
CAM-1 has the ability to negatively modulate the prothrom-
botic platelet^collagen interactions suggesting that it serves a
Fig. 2. Schematic representation of ITAM/ITIM-bearing receptor pathways in human platelets. Upon clustering of GPVI or FcQRIIA, the
ITAMs are phosphorylated to allow recruitment of Syk, which then phosphorylates PLC-Q2. GPVI and FcQRIIA can also recruit PI3-kinase,
which upon activation promotes rapid accumulation of PtdIns(3,4,5)P3 and downstream phosphorylation of the serine/threonine Akt or Bru-
ton’s tyrosine kinase, Btk. PtdInsP3 allows binding of PLC-Q2 to the membrane/cytoskeleton, enabling activation of the enzyme and generation
of secondary messengers including inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). These signalling events lead to calcium mobiliza-
tion and activation of PKC that promote platelet secretion and engagement of integrin KIIbL3 resulting in platelet aggregation. A negative feed-
back signal is created by the co-engagement of PECAM-1 with recruitment and activation of PTPs including SHP-2 delivering negative inhibi-
tory signalling to phosphorylate many of the components of the FcQRIIA and GPVI/FcR-Q chain ITAM-associated signalling pathways.
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pivotal role in preventing platelet thrombus formation. Our
recent studies have highlighted that PECAM-1 also serves as a
potent negative modulator of FcQRIIA-dependent platelet re-
sponses including HITS-mediated platelet aggregation (Thai,
L.M. and Jackson, D.E., unpublished observations). Both
these studies support a role for PECAM-1 in modulating
two important platelet active receptor pathways involving col-
lagen GPVI/FcR-Q chain and FcQRIIA (Fig. 2).
Recent studies have raised the possibility that PECAM-1
may negatively regulate non-ITAM-associated G-protein
coupled receptor signalling in platelets. In these experiments,
cross-linking of PECAM-1 inhibited thrombin and ADP-
mediated aggregation and secretion of platelets but only at
low dose concentrations of thrombin and ADP [51]. These
¢ndings have not been con¢rmed in studies of PECAM-1-
de¢cient platelets when examining a wide range of concentra-
tions of thrombin and ADP [26,50,53]. The reason for this
discrepancy is not clear and will require further investigation.
12.4. Function of PECAM-1 in endothelial cells
PECAM-1 is highly expressed in the vasculature with ap-
proximately one million copies of PECAM-1 reported on the
surface of endothelial cells [54]. Given its abundant expression
in endothelial cells, PECAM-1 has been demonstrated to be
involved in the initial formation and stabilization of cell^cell
contacts at lateral junctions of endothelial cells, the mainte-
nance of a vascular permeability barrier, modulation of cell
migration, transendothelial migration of monocytes and neu-
trophils and formation of new blood vessels in angiogenesis
[55^61]. Recent studies using cultured PECAM-1-de¢cient en-
dothelial cells have shown enhanced permeability changes in
response to histamine compared to PECAM-1-reconstituted
endothelial cells [49]. These studies provided con¢rmatory evi-
dence that PECAM-1 has an important function in mainte-
nance of a vascular permeability barrier.
Overexpression of a mutant form, Y686F PECAM-1 or a
truncated PECAM-1 construct devoid of the extracellular do-
main, in BAECs led to increased cell migration rates. These
studies highlighted that cytoplasmic domain ITIMs and the
extracellular domain of PECAM-1 may play an important
role in ‘inside-out’ and ‘outside-in’ signalling events to mod-
ulate endothelial cell migration [62]. In rat and murine models
of angiogenesis involving endothelial cells suspended in a
three-dimensional gel composed of type I collagen, polyclonal
and monoclonal antibodies directed to PECAM-1 were found
to block in vitro tube formation [61]. In a similar model,
endothelial cells that were incubated with anti-PECAM-1
antibodies showed reduced cell elongation and migration,
but no inhibition of the process of vacuole formation was
observed [63]. Thus, these studies highlighted that PECAM-
1 may play a role in the invasion, migration and/or extension
of pseudopods through a type I collagen matrix.
Maintenance of the lateral localization of PECAM-1 at the
junctions of endothelial cells requires cell contact. Without
cell contact, PECAM-1 remains di¡usely distributed within
the plane of the membrane of endothelial cells until it en-
counters its homophilic ligand, PECAM-1 on an adjacent
cell [56]. Recent studies with chimeric constructs of human
PECAM-1 have revealed that homophilic binding of
PECAM-1 on adjacent cells and positively charged sequences
(599RKAKAK604) juxtamembrane to the transmembrane do-
main of PECAM-1 are important for its localization to cell^
cell borders [64]. These highly charged amino acids may pro-
vide important docking sites of the recruitment of cytosolic
signalling molecules and/or cytoskeletal proteins to support
PECAM-1 localization and stabilization at cell^cell borders.
12.5. Function of PECAM-1 in leukocytes
An involvement of PECAM-1 has been implicated in neu-
trophil recruitment in vivo, neutrophil and monocyte che-
motaxis and transendothelial migration of monocytes and
neutrophils in vitro [60,65,66]. Anti-domain 1 PECAM-1
monoclonal antibodies and soluble PECAM-IgG chimeric
molecules have been shown to inhibit transmigration of leu-
kocytes through endothelium and in vivo neutrophil recruit-
ment [60,65,67^69].
In the process of macrophage phagocytosis, when a healthy
cell encounters a macrophage, signalling through bound PE-
CAM-1 receptors leads to the cells being repelled and disrup-
tion of cell adhesion. This is in contrast to dying cells under-
going apoptosis, where signalling through PECAM-1 is
somehow disrupted resulting in the cells not being repelled
and the balance being shifted towards engagement of macro-
phage engulfment receptors [42,70]. Recent studies implicate
PECAM-1 as a potent suppressor of Bax mitochondrial-medi-
ated apoptosis and suggests an unrecognized function for PE-
CAM-1 in the biology of blood and vascular cells [71].
12.6. Function of PECAM-1 in mast cells
In RBL-2H3 cells, aggregation of the high-a⁄nity Fc re-
ceptor for IgE, FcORI with anti-receptor antibodies induced
the tyrosine phosphorylation of PECAM-1 and recruitment of
SHP-2 PTP. This receptor-induced tyrosine phosphorylation
event was independent of Ca2þ £ux, activation of PKC and of
cell adhesion [29,30]. Recent studies have suggested that PE-
CAM-1 may play an important role in modulation of mast
cell function. PECAM-13=3 mice exhibited enhanced IgE-
mediated systemic anaphylaxis and showed increased sensitiv-
ity to local cutaneous IgE-dependent anaphylaxis compared
to PECAM-1þ=þ mice [72]. PECAM-13=3 bone marrow-de-
rived mast cells (BMMCs) showed enhanced serotonin release
following IgE stimulation and cross-linking with DNP-BSA in
vitro compared to WT BMMCs [72]. These functional studies
suggested that PECAM-1 acts as a counter-regulator in aller-
gic disease susceptibility and severity.
13. Concluding remarks
Based upon recent work we now consider PECAM-1 as a
member of the Ig-ITIM superfamily that is emerging as an
important receptor that has a repertoire of diverse functions
ranging from modulation of apoptosis, immune responses,
integrin-dependent adhesive events, angiogenesis, transendo-
thelial migration, macrophage phagocytosis, platelet respon-
siveness, mast cell degranulation and cell motility. Taken to-
gether, PECAM-1 has a pivotal role in modulating cell
signalling pathways that are essential in prevention of auto-
immunity, thrombosis, allergy and cancer. Further studies will
help to unravel the involvement of PECAM-1 in normal and
pathological processes.
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